RVTY — Revvity | Health Care | Breakout Trade Brief

SETUP

Price cleared the $124.54 breakout level on 1.67x average volume, closing near session highs at $124.70. The bar structure shows buyers defending the open and pushing into new territory, suggesting real demand rather than noise. The move is modest but clean — a controlled breakout rather than an exhaustion spike. Risk is defined at $121.46, offering a 3-point cushion with TP1 at $130.85 and TP2 at $134.95 on a 1:1.9 risk/reward. Acceptable but not exceptional.

CATALYSTS

Revvity recently reported Q2 2026 earnings, and the breakout occurring post-call suggests the market is digesting results positively or at minimum not selling off. The launch of the SuperFlex Prenatal Screening System targets smaller labs — an underserved market segment that could expand addressable revenue. Diagnostics and life science tools remain in a slow recovery cycle after several difficult quarters industry-wide, so any top-line stabilization or guidance hold would matter here.

RISKS

Fundamentals are largely unavailable — no P/E, no EPS, no beta — making it impossible to assess valuation risk or market sensitivity. That's a real blind spot. Volume at 1.67x is supportive but not emphatic; a higher-conviction breakout would show 2x or more. Signal quality scores only 50/100, flagging that this may not be an early-in-move setup — entry could be technically extended. If Q2 results showed only marginal improvement or weak forward guidance, this move fades quickly. Broader health care sector weakness or macro risk-off would pressure the name with limited fundamental anchor to defend it.

CONVICTION: Medium — The breakout has a real technical trigger and a post-earnings catalyst, but thin fundamental data, a middling signal score, and modest volume keep confidence in check.